Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

NCT03550859 Phase 4 UNKNOWN

This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.

Details

Lead sponsor	Yuhan Corporation
Phase	Phase 4
Status	UNKNOWN
Enrolment	374
Start date	2018-06-05
Completion	2021-12

Conditions

• Chronic Kidney Disease
• Proteinuria

Interventions

• Telmisartan/Rosuvastatin 40/10mg
• Telmisartan 40mg

Primary outcomes

• Rate of change from baseline to week 48 in Urine Protein to Creatinine Ratio (UPCR) — baseline, week 48

Countries

South Korea